ETFs Holding GALT »    GALT Historical Stock Prices »
GALT News Video: Thu, Dec 7, 2017, 1:11 PM — Thursday Sector Leaders: Drugs, Hospital & Medical Practitioners

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to develop therapies for fibrotic disease, severe skin disease, and cancer. Co.'s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. These compounds also may have application for drugs to treat other diseases and chronic health conditions. Co.'s key galectin-3 inhibitor is GR-MD-02, which has the potential to treat several diseases due to galectin-3's involvement in multiple key biological pathways such as immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). Self directed investors in Galectin Therapeutics Inc will be interested in keeping up with all Galectin Therapeutics Inc news they can find, both GALT news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on GALT. At RediNews, we simplify this task by presenting both GALT news releases originating from Galectin Therapeutics Inc itself, and GALT news from a variety of media outlets. Visitors can browse this news online and through our GALT RSS news feed.


GALT News — Articles, Videos, & Press Releases

Sum Up The Parts: SPSM Could Be Worth $35
Friday, March 8, 2019, 7:41 AM — ETF Channel
Galectin Therapeutics Breaks Below 200-Day Moving Average - Notable for GALT
Wednesday, February 27, 2019, 4:39 PM — Market News Video
Conatus (CNAT) Completes Enrollment in Phase II NASH Study
Wednesday, February 13, 2019, 2:36 PM — Zacks
Top Buys by Directors: Uihlein's $250.6K Bet on GALT
Thursday, February 7, 2019, 11:20 AM — Dividend Channel
Analysts Anticipate SPSM Will Reach $35
Thursday, January 31, 2019, 7:59 AM — ETF Channel
How The Parts Add Up: SPSM Headed For $35
Friday, December 28, 2018, 9:50 AM — ETF Channel
Galectin Therapeutics Breaks Above 200-Day Moving Average - Bullish for GALT
Friday, November 2, 2018, 4:31 PM — Market News Video
First Week of January 2021 Options Trading For Galectin Therapeutics (GALT)
Tuesday, September 18, 2018, 11:18 AM — Stock Options Channel
The Implied Analyst 12-Month Target For DWAS
Tuesday, September 11, 2018, 8:28 AM — ETF Channel
First Week of GALT September 21st Options Trading
Monday, July 30, 2018, 11:31 AM — Stock Options Channel
Analysts Predict 10% Upside For DWAS
Monday, July 30, 2018, 8:28 AM — ETF Channel
GALT Crosses Above Average Analyst Target
Monday, June 18, 2018, 8:04 AM — ETF Channel
GALT is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

SSH News

Whether you use an enterprise information portal to update a corporate relations page, or have a handmade website with investor content in it, chances are you have come across the term "RSS" — Really Simple Syndication. Web page finance website experts and novices alike are welcome to integrate any of the RediNews RSS feeds found on the stock market content pages within our website. Simply navigate to any RediNews news page by specific ticker symbol, then click the RSS icon for any news page to reach the associated RSS feed (the icon will look like this): . Our news would be ideal paired with free stock chart and investor content, querying for the same specific stock ticker symbol presented to the user. While experience with flash and cobranded content would be ideal for integrating our news in a cool and unique way such as within a stock market ticker or stock screener feature, our feeds can also be integrated as extra links to enhance your financial portal content with dynamic stock content that updates every time there is new news tagged with the stock, giving your visitors another reason to check back to your website in the future.

GALT News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.